Effects of Selective Matrix Metalloproteinase Inhibitor (PG-116800) to Prevent Ventricular Remodeling After Myocardial Infarction
Results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) Trial
Michael P. Hudson, MD, FACC*,
Paul W. Armstrong, MD, FACC
,c,
Witold Ruzyllo, MD
,d,
Jose Brum, MD
,a,
Lisa Cusmano, MS
,a,
Piotr Krzeski, MD
,a,
Robert Lyon, PhD
,a,
Miguel Quinones, MD, FACC||,d,
Pierre Theroux, MD, FACC¶,b,d,
Diana Sydlowski, MS*,
Henry E. Kim, MD, FACC*,
Mario J. Garcia, MD, FACC#,
Wael A. Jaber, MD, FACC# and
W. Douglas Weaver, MD, FACC*,d,*
* Henry Ford Heart and Vascular Institute, Detroit, Michigan
University of Alberta, Edmonton, Alberta, Canada
National Institute of Cardiology, Warsaw, Poland
Procter & Gamble Pharmaceuticals, Cincinnati, Ohio
|| Montreal Heart Institute, Montreal, Quebec, Canada
¶ Baylor College of Medicine, Houston, Texas
# Cleveland Clinic Foundation, Cleveland, Ohio.

View larger version (18K):
[in a new window]
|
Figure 1 Primary end point/change in left ventricular diastolic volume index (LVEDVI), baseline to 90 days.
|
|
Copyright © 2006 by the American College of Cardiology Foundation.